These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31971469)

  • 1. Cost-effectiveness of mirogabalin for the treatment of post-herpetic neuralgia in Taiwan.
    Ye X; Gray E; Wang YF; Wang SJ
    J Med Econ; 2020 May; 23(5):529-536. PubMed ID: 31971469
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan.
    Gray E; Ye X; Wang YF; Wang SJ
    Value Health Reg Issues; 2021 May; 24():148-156. PubMed ID: 33582418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M; Liedgens H; Nuijten M
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy.
    Hong LM; Liu JM; Lin L; Huang CC; Chen R; Lin WW
    Eur J Pharm Sci; 2024 Jun; 197():106777. PubMed ID: 38649099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
    J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China.
    Zeng F; Wang M; Zhang D
    Ann Palliat Med; 2021 Apr; 10(4):4493-4501. PubMed ID: 33894728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
    Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
    BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients.
    Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S; Sugihara M
    Pain; 2019 May; 160(5):1175-1185. PubMed ID: 30913164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
    Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
    J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
    Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S
    Medicine (Baltimore); 2020 Sep; 99(36):e21976. PubMed ID: 32899037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB; Noyes K; Holloway RG
    J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
    Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
    Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
    Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
    J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
    Alyoubi RA; Alshareef AA; Aldughaither SM; Aljaroudi AM; Alabdulwahed A; Alduraibi FM; Masoud AT; Abu-Zaid A
    Int J Clin Pract; 2021 May; 75(5):e13744. PubMed ID: 32991782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
    Merante D; Rosenstock J; Sharma U; Feins K; Hsu C; Vinik A;
    Pain Med; 2017 Nov; 18(11):2198-2207. PubMed ID: 28371941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.
    Arnold LM; Whitaker S; Hsu C; Jacobs D; Merante D
    Curr Med Res Opin; 2019 Oct; 35(10):1825-1835. PubMed ID: 31284771
    [No Abstract]   [Full Text] [Related]  

  • 19. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the
    Domon Y; Arakawa N; Inoue T; Matsuda F; Takahashi M; Yamamura N; Kai K; Kitano Y
    J Pharmacol Exp Ther; 2018 Jun; 365(3):573-582. PubMed ID: 29563324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.